This study aims to establish CD9 as a prognostic biomarker for glioma through integrative multi-omics analysis, delineate its interaction networks driving tumor progression, and identify therapeutic agents targeting CD9-associated pathways. The gene discussed is CD9; the disease is central nervous system cancer.